FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens

The US Food and Drug Administration (FDA) has allowed marketing of a rapid diagnostic test (RDT) to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola. This is the first rapid diagnostic test the FDA has allowed to be marketed in the US for the Ebola Virus Disease (EVD).

WHO Signals Alarm Over Possible Unreported Ebola Cases in Tanzania

On September 10, 2019, through its regular event-based surveillance process, WHO received unofficial reports regarding the death of a person with suspected Ebola Virus Disease (EVD) case in Dar es Salaam, United Republic of Tanzania.  On  September 11, 2019, through its regular event-based surveillance process, WHO was made aware of unofficial reports that a RT-PCR test performed at the Tanzanian National Health Laboratory was positive for EVD for this patient.

Modern science has delivered the world powerful tools to defeat Ebola. It is not enough

This article acknowledges the importance of recent Ebola therapeutics and vaccine breakthroughs but also highlights the importance of infection control, community engagement, and disease surveillance as deciding factors in combating the Ebola crisis in the Democratic Republic of Congo.

Two New Treatments Significantly Lower Ebola Death Rate

Two treatments for Ebola which were undergoing trials in the Democratic Republic of Congo have been stopped early due to their success in treating Ebola. The two treatments will now be made widely available. One of the drugs is REGN-EB3, a cocktail of three monoclonal antibodies developed by Regeneron Pharmaceuticals. The other drug is mAb114, which is now being developed with Ridgeback Biotherapeutics.